Zoetis EVP Acquires $9.4k in Phantom Stock Units via Savings Plan
Zoetis Inc.
Subscribe to track ZTS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Zoetis EVP Acquires $9.4k in Phantom Stock Units
Company: Zoetis Inc. (ZTS) Form: 4 | Filed: 2025-10-14 Significance: Low
Insider: Lagano Roxanne Title: Executive Vice President | Relationship: Officer
Transaction: • Type: Grant • Shares: 201.7366 • Price: $46.71 • Value: $9,423 • Owned After: 28,624.727
Key Insight: This is a routine acquisition of phantom stock units through the company's Supplemental Savings Plan, not an open-market purchase. The value is minor for an executive, indicating low trading significance.
Market Context: The transaction is part of a deferred compensation plan and does not reflect a direct investment decision by the insider.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Zoetis Inc. (ZTS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: An Executive Vice President acquired a small number of phantom stock units as part of a routine company savings plan, not as a direct investment decision. The transaction has minimal market significance.
- Market Impact: Neutral. This type of transaction is common for executive compensation and is not expected to influence the stock price or trading volume.
Company Information
| Field | Value |
|---|---|
| Company | Zoetis Inc. |
| Ticker Symbol | ZTS |
| CIK | 0001555280 |
| Industry | PHARMACEUTICAL PREPARATIONS [2834] |
Insider Information
| Field | Value |
|---|---|
| Name | Lagano Roxanne |
| CIK | 0001567878 |
| Title/Position | Executive Vice President |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-10-10 |
| Transaction Code | A (Grant, award, or other acquisition) |
| Security Type | Phantom Stock Unit |
| Shares Involved | 201.7366 |
| Price Per Share | $46.71 |
| Total Value | $9,423.00 |
| Shares Owned After | 28,624.727 |
| Ownership Type | Direct |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction is an acquisition of derivative securities (phantom stock) under a supplemental savings plan, as noted in the filing's footnotes. This is a form of deferred compensation and does not represent an open-market purchase by the insider. The total value is negligible for an executive, signaling no new insider sentiment.
Volume & Sentiment
- Expected Volume Impact: None. Compensation-related acquisitions do not affect trading volume.
- Sentiment Indicator: Neutral. The transaction is procedural and does not provide a bullish or bearish signal to the market.
Investment Insights
Positive Market Indicators
- N/A. This filing does not present any positive market indicators.
Risk Factors
- N/A. This filing does not present any new risk factors.
Key Takeaways
- Routine Compensation: The acquisition is part of the Zoetis Supplemental Savings Plan, a standard deferred compensation vehicle for executives.
- Derivative Security: The transaction involves phantom stock units, which are cash-settled upon separation from service and are not common stock.
- Low Significance: The small transaction value ($9,423) reinforces that this is not a strategic investment by the insider but a routine, automated part of their compensation package.
Contextual Analysis
Timing Significance
- The timing of the transaction is tied to the mechanics of the savings plan and does not appear to be correlated with any specific market event or inside information.
Transaction Context
- Footnote 1 clarifies that these units were acquired via the Zoetis Supplemental Savings Plan and are settled in cash. This confirms the nature of the transaction as compensation, not an investment.
- Footnote 2 explains that each phantom stock unit's value is tied to the market value of Zoetis common stock, making it a derivative instrument.
Company Context
- Zoetis is a major company in the pharmaceutical and animal health sector. Analysis of such filings should be viewed in the broader context of the company's performance, industry trends, and overall executive compensation strategy.
Risk Assessment
Risk Level: Low
Risk Factors
- This filing does not introduce any new risks to the investment thesis for Zoetis.
Market Considerations
- Investors should differentiate between discretionary open-market trades and non-discretionary, compensation-related acquisitions like this one.
- The filing is a matter of routine compliance and transparency, not a signal of a change in the company's or insider's outlook.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-14 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.